Exaggeration of median progression-free survival (PFS) by blinded, independent, central review (BICR).
Andrew Stone, Antony Sabin(GlaxoSmithKline (Sri Lanka)), Val Gebski(The University of Sydney), Richard Davidson(AstraZeneca (United Kingdom)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Jonathan Bartlett(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842